Version May 2024
Warts: Topical: Applied by physician only.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Postmarketing:
Cardiovascular: Tachycardia (Singh 2022)
Dermatologic: Burn (chemical burn) (Singh 2022), cicatrix of skin (Singh 2022), dermal ulcer (Singh 2022), erythema of skin (Singh 2022), skin edema (Singh 2022), urticaria (Singh 2022)
Gastrointestinal: Abdominal pain (Filley 1982), diarrhea (Singh 2022), nausea (Singh 2022), paralytic ileus (Filley 1982, Singh 2022), vomiting (Singh 2022)
Genitourinary: Anuria (Singh 2022), oliguria (Singh 2022), urinary retention (Filley 1982)
Hematologic & oncologic: Anemia (Singh 2022), leukocytosis (Singh 2022), leukopenia (Singh 2022), thrombocytopenia (Singh 2022)
Hepatic: Hepatic impairment (Filley 1982), increased liver enzymes (Singh 2022)
Local: Local inflammation (acute inflammatory reaction with necrosis) (Singh 2022)
Nervous system: Absent reflexes (Filley 1982), agitation (Filley 1982), ataxia (Filley 1982), coma (Singh 2022), confusion (Singh 2022), headache (Singh 2022), hyperpyrexia (Singh 2022), hypotonia (Filley 1982), lethargy (Singh 2022), paresthesia (Filley 1982), peripheral neuropathy (Filley 1982), polyneuropathy (Filley 1982), psychotic symptoms (including auditory hallucination, delusion paranoid disorder, and visual hallucination) (Filley 1982), sensorimotor neuropathy (Filley 1982)
Renal: Renal failure syndrome (Filley 1982)
Respiratory: Tachypnea (Singh 2022)
Miscellaneous: Fever (Singh 2022)
Not to be used on bleeding warts, birthmarks, moles, or warts with hair growth; not to be used by patients with diabetes or poor circulation; concurrent use of steroids; pregnancy; breastfeeding.
Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Other warnings/precautions:
• Appropriate use: Use of large amounts of drug should be avoided. For external use only; avoid contact with the eyes as it can cause severe corneal damage; do not apply to moles, birthmarks, or unusual warts; do not use if wart or surrounding tissue is inflamed/irritated or contains open lesions. To be applied by a health care professional only.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, External:
Podocon-25: 25% (15 mL)
No
Solution (Podocon-25 External)
25% (per mL): $8.17
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, External:
Podofilm: 25% ([DSC])
Topical: For external use only; avoid contact with eyes. To be applied by medical professional only; cleanse and dry affected area prior to application. Shake well prior to use. Use applicator provided with product to apply sparingly to lesions; avoid contact with healthy tissue; allow to dry thoroughly. When applying for the first time, leave on for only 30 to 40 minutes to determine patient sensitivity. After first, use may leave on 1 to 4 hours depending on severity of lesion; systemic absorption may occur with prolonged contact. Do not treat large areas or many warts at one time. Do not use if wart or surrounding tissue is inflamed or irritated. Do not use on bleeding warts, moles, birthmarks, or unusual warts with hair growing from them. Remove drug with alcohol or soap and water once treatment time has elapsed.
Warts: Topical treatment of soft external genital (venereal) warts (condylomata acuminata); compound benzoin tincture generally is used as the medium for topical application.
Note: CDC sexually transmitted infections guidelines no longer recommend podophyllum resin as an option for the treatment of external genital warts due to reports of systemic toxicity when applied incorrectly, and because of the availability of safer alternative agents. Use may be considered for provider-administered treatment under select conditions (CDC [Workowski 2021]).
The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.
None known.
There are no known significant interactions.
Fetal abnormalities, fetal death, and stillbirth have been reported following use of podophyllum resin in patients who are pregnant. Use is contraindicated during pregnancy.
It is not known of podophyllum resin is present breast milk.
Use in breastfeeding patients is contraindicated by the manufacturer.
Directly affects epithelial cell metabolism by arresting mitosis through binding to a protein subunit of spindle microtubules (tubulin)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
